2
|
Cytometric analysis of cell suspension generated by cavitron ultrasonic surgical aspirator in pediatric brain tumors. J Neurooncol 2019; 143:15-25. [PMID: 30827009 DOI: 10.1007/s11060-019-03135-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 02/23/2019] [Indexed: 12/15/2022]
Abstract
PURPOSE The aim of this study was to test the possibility of using specimens obtained by a cavitron ultrasonic surgical aspirator (CUSA) in flow and mass cytometry investigations of pediatric brain tumors. METHODS CUSA specimens obtained from 19 pediatric patients with brain tumors were investigated. Flow and mass cytometry methods were applied to analyze the composition of material collected using the CUSA. Cell suspensions were prepared from CUSA aspirates. Then sample viability was assessed by conventional flow cytometry and subsequently stained with a panel of 31 metal-labeled antibodies. RESULTS Viability assessment was performed using conventional flow cytometry. Viability of cells in the acquired samples was below 50% in 16 of 19 cases. A mass cytometry investigation and subsequent analysis enabled us to discriminate brain tumor cells from contaminating leukocytes, whose proportions varied across the specimens. The addition of the viability marker cisplatin directly into the mass cytometry panel gave the means to selecting viable cells only for subsequent analyses. The proportion of non-viable cells was higher among tumor cells compared leukocytes. CONCLUSIONS When the analysis of the tumor cell immunophenotype is performed with markers for determining viability, the expression of the investigated markers can be evaluated. Suitable markers can be selected by high-throughput methods, such as mass cytometry, and those that are diagnostically relevant can be investigated using flow cytometry, which is more flexible in terms of time.
Collapse
|
3
|
du Plessis WJ, Keyser A, Walzl G, Loxton AG. Phenotypic analysis of peripheral B cell populations during Mycobacterium tuberculosis infection and disease. JOURNAL OF INFLAMMATION-LONDON 2016; 13:23. [PMID: 27478412 PMCID: PMC4966581 DOI: 10.1186/s12950-016-0133-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 07/22/2016] [Indexed: 01/31/2023]
Abstract
BACKGROUND Mycobacterium tuberculosis (Mtb) remains an unresolved threat resulting in great annual loss of life. The role of B cells during the protective immunity to Mtb is still unclear. B cells have been described as effector cells in addition to their role as antibody producing cells during disease. Here we aim to identify and characterize the frequency of peripheral B-cell subpopulations during active Tuberculosis and over treatment response. Analysis were done for both class switched (CS) and non-class switched (NCS) phenotypes. METHODS We recruited participants with active untreated pulmonary Tuberculosis, other lung diseases and healthy community controls. All groups were followed up for one week from recruitment and the TB cases till the end of treatment (month 6). RESULTS Peripheral blood samples were collected, stained with monoclonal antibodies to CD19(+) cells, Immunoglobulin (Ig) M, plasma cells (CD 138(+)), marker of memory (CD27(+)), immune activation (CD23(+)) and acquired on a flow cytometer. Circulating Marginal zone B cells (CD19(+)IgM(+)CD23(-)CD27(+)) and memory phenotypes are able to distinguish between TB diagnosis and end of treatment. The frequency of mature B cells from TB cases are lower than that of other-lung diseases at diagnosis. A subpopulation of activated memory B cells (CD19(+)IgM(+)CD23(+)CD27(+)) cells are present at the end of TB treatment. CONCLUSIONS This study identified distinctive B cell subpopulations present during active TB disease and other lung disease conditions. These cell populations warrants further examination in larger studies as it may be informative as cell markers or as effectors/regulators in TB disease or TB treatment response.
Collapse
Affiliation(s)
- Willem J du Plessis
- SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000 South Africa
| | - Alana Keyser
- Clinical Laboratory Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Gerhard Walzl
- SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000 South Africa
| | - André G Loxton
- SA MRC Centre for TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000 South Africa
| |
Collapse
|
4
|
Svojgr K, Sumerauer D, Puchmajerova A, Vicha A, Hrusak O, Michalova K, Malis J, Smisek P, Kyncl M, Novotna D, Machackova E, Jencik J, Pycha K, Vaculik M, Kodet R, Stary J. Fanconi anemia with biallelic FANCD1/BRCA2 mutations - Case report of a family with three affected children. Eur J Med Genet 2015; 59:152-7. [PMID: 26657402 DOI: 10.1016/j.ejmg.2015.11.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 11/24/2015] [Accepted: 11/28/2015] [Indexed: 01/02/2023]
Abstract
Fanconi anemia, complementation group D1 with bi-allelic FANCD1 (BRCA2) mutations, is a very rare genetic disorder characterized by early onset of childhood malignancies, including acute leukemia, brain cancer and nephroblastoma. Here, we present a case report of a family with 3 affected children in terms of treatment outcome, toxicity and characterization of the malignancies using comprehensive cytogenetic analysis. The first child was diagnosed with T-cell acute lymphoblastic leukemia when he was 11 months old. During chemotherapy, he suffered from repeated pancytopenia, sepsis and severe vincristine polyneuropathy, and 18 months after primary diagnosis, he succumbed to secondary acute monocytic leukemia. The second child was diagnosed with stage 2 triphasic nephroblastoma (Wilms tumor), when he was 3 years and 11 months old. During chemotherapy, he suffered from vincristine polyneuropathy. Currently, he is in complete remission, 29 months following the initial diagnosis. The third child was diagnosed with medulloblastoma with classical histology, when she was 4 years and 5 months old. After the first cycle of chemotherapy, she suffered from prolonged pancytopenia, sepsis and severe skin and mucosal toxicity. Six weeks after primary diagnosis, a first relapse in the posterior fossa was diagnosed, and at 7 and half months after primary diagnosis, a second relapse was diagnosed that led to the patient's death. Our case report underscores tumor heterogeneity, treatment toxicity and poor outcome in Fanconi anemia patients of complementation group D1.
Collapse
Affiliation(s)
- Karel Svojgr
- Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
| | - David Sumerauer
- Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Alena Puchmajerova
- Department of Biology and Medical Genetics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Ales Vicha
- Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Ondrej Hrusak
- Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Kyra Michalova
- Center of Oncocytogenetics, General Teaching Hospital, Prague, Czech Republic
| | - Josef Malis
- Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Petr Smisek
- Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Martin Kyncl
- Department of Radiology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Drahuse Novotna
- Department of Biology and Medical Genetics, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Eva Machackova
- Department of Epidemiology and Cancer Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | | | - Karel Pycha
- Department of Pediatric Surgery, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Miroslav Vaculik
- Department of Neurosurgery, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Roman Kodet
- Department of Pathology and Molecular Medicine, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| | - Jan Stary
- Department of Pediatric Hematology and Oncology, Charles University in Prague, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
| |
Collapse
|
5
|
Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VHJ, Novakova M, Mejstrikova E, Hrusak O, Böttcher S, Karsch D, Sędek Ł, Trinquand A, Boeckx N, Caetano J, Asnafi V, Lucio P, Lima M, Helena Santos A, Bonaccorso P, van der Sluijs-Gelling AJ, Langerak AW, Martin-Ayuso M, Szczepański T, van Dongen JJM, Orfao A. Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds. Cytometry A 2014; 87:145-56. [DOI: 10.1002/cyto.a.22581] [Citation(s) in RCA: 108] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Revised: 08/28/2014] [Accepted: 10/06/2014] [Indexed: 01/21/2023]
Affiliation(s)
- Tomas Kalina
- CLIP - Childhood Leukemia Investigation Prague and Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine; Charles University Prague and University Hospital Motol; Prague Czech Republic
| | - Juan Flores-Montero
- Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Servicio General de Citometria (NUCLEUS) and Department of Medicine; University of Salamanca; Salamanca Spain
| | - Quentin Lecrevisse
- Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Servicio General de Citometria (NUCLEUS) and Department of Medicine; University of Salamanca; Salamanca Spain
| | - Carlos E. Pedreira
- Systems & Computing Department (PESC), COPPE - Engineering Graduate Program; Federal University of Rio de Janeiro; Rio de Janeiro (UFRJ) Brazil
| | | | - Michaela Novakova
- CLIP - Childhood Leukemia Investigation Prague and Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine; Charles University Prague and University Hospital Motol; Prague Czech Republic
| | - Ester Mejstrikova
- CLIP - Childhood Leukemia Investigation Prague and Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine; Charles University Prague and University Hospital Motol; Prague Czech Republic
| | - Ondrej Hrusak
- CLIP - Childhood Leukemia Investigation Prague and Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine; Charles University Prague and University Hospital Motol; Prague Czech Republic
| | - Sebastian Böttcher
- Second Department of Medicine; University Hospital of Schleswig-Holstein; Campus Kiel Kiel Germany
| | - Dennis Karsch
- Second Department of Medicine; University Hospital of Schleswig-Holstein; Campus Kiel Kiel Germany
| | - Łukasz Sędek
- Department of Pediatric Hematology and Oncology; Zabrze Medical University of Silesia; Katowice Poland
| | - Amelie Trinquand
- Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM) U1151, and Laboratory of Onco-Hematology; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades Paris France
| | - Nancy Boeckx
- Department of Laboratory Medicine, University Hospitals Leuven and Department of Oncology; Catholic University Leuven; Leuven Belgium
| | - Joana Caetano
- Hemato-Oncology Laboratory, Department of Hematology; Portuguese Institute of Oncology (IPOLFG); Lisbon Portugal
| | - Vahid Asnafi
- Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM) U1151, and Laboratory of Onco-Hematology; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades Paris France
| | - Paulo Lucio
- Hemato-Oncology Laboratory, Department of Hematology; Portuguese Institute of Oncology (IPOLFG); Lisbon Portugal
| | - Margarida Lima
- Laboratory of Flow Cytometry, Department of Hematology; Hospital de Santo António, Centro Hospitalar do Porto; Porto Portugal
| | - Ana Helena Santos
- Laboratory of Flow Cytometry, Department of Hematology; Hospital de Santo António, Centro Hospitalar do Porto; Porto Portugal
| | - Paola Bonaccorso
- M.Tettamanti Research Center, Pediatric Clinic University of Milan Bicocca; Monza Italy
| | | | - Anton W. Langerak
- Department of Immunology; Erasmus MC University Medical Center; Rotterdam Netherlands
| | | | - Tomasz Szczepański
- Department of Pediatric Hematology and Oncology; Zabrze Medical University of Silesia; Katowice Poland
| | | | - Alberto Orfao
- Cancer Research Center (IBMCC-CSIC/USAL-IBSAL), Servicio General de Citometria (NUCLEUS) and Department of Medicine; University of Salamanca; Salamanca Spain
| |
Collapse
|